Polycystic ovary syndrome (PCOS) trilogy: A translational and clinical review

Helen Mason, Annamaria Colao, Ulrike Blume-Peytavi, Suman Rice, Asjid Qureshi, Laura Pellatt, Francesco Orio, Stephen Atkin

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Although PCOS is the focus of intense research, the importance of the translation and application of this research to the clinical setting cannot be underestimated. The PCOS SIG's annual meeting showcased three different aspects of the disease, with the overall aim of encouraging interdisciplinary collaboration and networking in this important area. PCOS is one of the most common conditions in women of childbearing age, and is the most common cause of hyperandrogenism in this cohort. Dr Mason detailed the factors implicated in the cause of the ovulatory dysfunction in PCOS. It is clear that there are differences in the production of many of the paracrine signalling hormones between normal and polycystic ovaries. Although subtle changes can be observed in the inhibin/activin family it is difficult to assess the in vivo impact of such changes on follicle growth. Likewise, there are clearly alterations in the IGF/IGFBP system and in the production of various androgenic and other steroids and whereas these are not without interest, it is impossible to determine whether they reflect defective follicle function or cause it. It can however, be seen that the changes in testosterone and and androstenedione are considerable and intrinsic and are likely candidates for disrupting folliculogenesis in the early stages. It is the sheer magnitude of the increase in AMH production that differentiates it from other factors and underlines the likelihood that this will prove to be an important factor in the pathogenesis of PCOS. Professor Colao detailed the CVR factors present in PCOS. However, it was noted that there is a paucity both of long-term data for well-characterized women with PCOS, and for large-scale prospective clinical trials to determine the outcome morbidity and mortality of CVD in PCOS subjects. Furthermore, the link between PCOS and primary cardiovascular events has not yet been demonstrated. Professor Blume-Peytavi urged that the impact of the dermatological manifestations of this disorder should not be underestimated, describing how many women find these symptoms extremely debilitating, affecting many aspects of their lives. For patients suffering from PCOS, treatment options include reduction of androgen production and action, lifestyle modification, oral contraceptives, antiandrogens, and insulin-sensitizing agents as well as topical treatment of acne, seborrhoea and AGA. Local management of hirsutism should also include photoepilation combined with eflornithine cream.

Original languageEnglish
Pages (from-to)831-844
Number of pages14
JournalClinical Endocrinology
Volume69
Issue number6
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Paracrine Communication
Seborrheic Dermatitis
Eflornithine
Hyperandrogenism
Androgen Antagonists
Activins
Hirsutism
Insulin-Like Growth Factor Binding Proteins
Inhibins
Androstenedione
Acne Vulgaris
Oral Contraceptives
Research
Androgens
Testosterone
Life Style
Ovary
Steroids
Clinical Trials

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Polycystic ovary syndrome (PCOS) trilogy : A translational and clinical review. / Mason, Helen; Colao, Annamaria; Blume-Peytavi, Ulrike; Rice, Suman; Qureshi, Asjid; Pellatt, Laura; Orio, Francesco; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 69, No. 6, 12.2008, p. 831-844.

Research output: Contribution to journalReview article

Mason, H, Colao, A, Blume-Peytavi, U, Rice, S, Qureshi, A, Pellatt, L, Orio, F & Atkin, S 2008, 'Polycystic ovary syndrome (PCOS) trilogy: A translational and clinical review', Clinical Endocrinology, vol. 69, no. 6, pp. 831-844. https://doi.org/10.1111/j.1365-2265.2008.03329.x
Mason H, Colao A, Blume-Peytavi U, Rice S, Qureshi A, Pellatt L et al. Polycystic ovary syndrome (PCOS) trilogy: A translational and clinical review. Clinical Endocrinology. 2008 Dec;69(6):831-844. https://doi.org/10.1111/j.1365-2265.2008.03329.x
Mason, Helen ; Colao, Annamaria ; Blume-Peytavi, Ulrike ; Rice, Suman ; Qureshi, Asjid ; Pellatt, Laura ; Orio, Francesco ; Atkin, Stephen. / Polycystic ovary syndrome (PCOS) trilogy : A translational and clinical review. In: Clinical Endocrinology. 2008 ; Vol. 69, No. 6. pp. 831-844.
@article{7800f0ee016d4a3abf90dd3ef85bd366,
title = "Polycystic ovary syndrome (PCOS) trilogy: A translational and clinical review",
abstract = "Although PCOS is the focus of intense research, the importance of the translation and application of this research to the clinical setting cannot be underestimated. The PCOS SIG's annual meeting showcased three different aspects of the disease, with the overall aim of encouraging interdisciplinary collaboration and networking in this important area. PCOS is one of the most common conditions in women of childbearing age, and is the most common cause of hyperandrogenism in this cohort. Dr Mason detailed the factors implicated in the cause of the ovulatory dysfunction in PCOS. It is clear that there are differences in the production of many of the paracrine signalling hormones between normal and polycystic ovaries. Although subtle changes can be observed in the inhibin/activin family it is difficult to assess the in vivo impact of such changes on follicle growth. Likewise, there are clearly alterations in the IGF/IGFBP system and in the production of various androgenic and other steroids and whereas these are not without interest, it is impossible to determine whether they reflect defective follicle function or cause it. It can however, be seen that the changes in testosterone and and androstenedione are considerable and intrinsic and are likely candidates for disrupting folliculogenesis in the early stages. It is the sheer magnitude of the increase in AMH production that differentiates it from other factors and underlines the likelihood that this will prove to be an important factor in the pathogenesis of PCOS. Professor Colao detailed the CVR factors present in PCOS. However, it was noted that there is a paucity both of long-term data for well-characterized women with PCOS, and for large-scale prospective clinical trials to determine the outcome morbidity and mortality of CVD in PCOS subjects. Furthermore, the link between PCOS and primary cardiovascular events has not yet been demonstrated. Professor Blume-Peytavi urged that the impact of the dermatological manifestations of this disorder should not be underestimated, describing how many women find these symptoms extremely debilitating, affecting many aspects of their lives. For patients suffering from PCOS, treatment options include reduction of androgen production and action, lifestyle modification, oral contraceptives, antiandrogens, and insulin-sensitizing agents as well as topical treatment of acne, seborrhoea and AGA. Local management of hirsutism should also include photoepilation combined with eflornithine cream.",
author = "Helen Mason and Annamaria Colao and Ulrike Blume-Peytavi and Suman Rice and Asjid Qureshi and Laura Pellatt and Francesco Orio and Stephen Atkin",
year = "2008",
month = "12",
doi = "10.1111/j.1365-2265.2008.03329.x",
language = "English",
volume = "69",
pages = "831--844",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Polycystic ovary syndrome (PCOS) trilogy

T2 - A translational and clinical review

AU - Mason, Helen

AU - Colao, Annamaria

AU - Blume-Peytavi, Ulrike

AU - Rice, Suman

AU - Qureshi, Asjid

AU - Pellatt, Laura

AU - Orio, Francesco

AU - Atkin, Stephen

PY - 2008/12

Y1 - 2008/12

N2 - Although PCOS is the focus of intense research, the importance of the translation and application of this research to the clinical setting cannot be underestimated. The PCOS SIG's annual meeting showcased three different aspects of the disease, with the overall aim of encouraging interdisciplinary collaboration and networking in this important area. PCOS is one of the most common conditions in women of childbearing age, and is the most common cause of hyperandrogenism in this cohort. Dr Mason detailed the factors implicated in the cause of the ovulatory dysfunction in PCOS. It is clear that there are differences in the production of many of the paracrine signalling hormones between normal and polycystic ovaries. Although subtle changes can be observed in the inhibin/activin family it is difficult to assess the in vivo impact of such changes on follicle growth. Likewise, there are clearly alterations in the IGF/IGFBP system and in the production of various androgenic and other steroids and whereas these are not without interest, it is impossible to determine whether they reflect defective follicle function or cause it. It can however, be seen that the changes in testosterone and and androstenedione are considerable and intrinsic and are likely candidates for disrupting folliculogenesis in the early stages. It is the sheer magnitude of the increase in AMH production that differentiates it from other factors and underlines the likelihood that this will prove to be an important factor in the pathogenesis of PCOS. Professor Colao detailed the CVR factors present in PCOS. However, it was noted that there is a paucity both of long-term data for well-characterized women with PCOS, and for large-scale prospective clinical trials to determine the outcome morbidity and mortality of CVD in PCOS subjects. Furthermore, the link between PCOS and primary cardiovascular events has not yet been demonstrated. Professor Blume-Peytavi urged that the impact of the dermatological manifestations of this disorder should not be underestimated, describing how many women find these symptoms extremely debilitating, affecting many aspects of their lives. For patients suffering from PCOS, treatment options include reduction of androgen production and action, lifestyle modification, oral contraceptives, antiandrogens, and insulin-sensitizing agents as well as topical treatment of acne, seborrhoea and AGA. Local management of hirsutism should also include photoepilation combined with eflornithine cream.

AB - Although PCOS is the focus of intense research, the importance of the translation and application of this research to the clinical setting cannot be underestimated. The PCOS SIG's annual meeting showcased three different aspects of the disease, with the overall aim of encouraging interdisciplinary collaboration and networking in this important area. PCOS is one of the most common conditions in women of childbearing age, and is the most common cause of hyperandrogenism in this cohort. Dr Mason detailed the factors implicated in the cause of the ovulatory dysfunction in PCOS. It is clear that there are differences in the production of many of the paracrine signalling hormones between normal and polycystic ovaries. Although subtle changes can be observed in the inhibin/activin family it is difficult to assess the in vivo impact of such changes on follicle growth. Likewise, there are clearly alterations in the IGF/IGFBP system and in the production of various androgenic and other steroids and whereas these are not without interest, it is impossible to determine whether they reflect defective follicle function or cause it. It can however, be seen that the changes in testosterone and and androstenedione are considerable and intrinsic and are likely candidates for disrupting folliculogenesis in the early stages. It is the sheer magnitude of the increase in AMH production that differentiates it from other factors and underlines the likelihood that this will prove to be an important factor in the pathogenesis of PCOS. Professor Colao detailed the CVR factors present in PCOS. However, it was noted that there is a paucity both of long-term data for well-characterized women with PCOS, and for large-scale prospective clinical trials to determine the outcome morbidity and mortality of CVD in PCOS subjects. Furthermore, the link between PCOS and primary cardiovascular events has not yet been demonstrated. Professor Blume-Peytavi urged that the impact of the dermatological manifestations of this disorder should not be underestimated, describing how many women find these symptoms extremely debilitating, affecting many aspects of their lives. For patients suffering from PCOS, treatment options include reduction of androgen production and action, lifestyle modification, oral contraceptives, antiandrogens, and insulin-sensitizing agents as well as topical treatment of acne, seborrhoea and AGA. Local management of hirsutism should also include photoepilation combined with eflornithine cream.

UR - http://www.scopus.com/inward/record.url?scp=55949108111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949108111&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2008.03329.x

DO - 10.1111/j.1365-2265.2008.03329.x

M3 - Review article

C2 - 18616705

AN - SCOPUS:55949108111

VL - 69

SP - 831

EP - 844

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -